Pharvaris N.V. Ordinary Shares Stock Prediction
AI-powered sentiment analysis and prediction trends for PHVS, updated each market day.
PHVS AI Sentiment
AI predicts Pharvaris N.V. Ordinary Shares stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Pharvaris N.V. Ordinary Shares
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Exchange
Market Cap
$1,770,589,741
Cap Tier
Employees
129
Listed Since
Feb. 5, 2021
Website
PHVS Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
PHVS Volatility
Pharvaris N.V. Ordinary Shares has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
